Neoadjuvant window studies of metformin and biomarker development for drugs targeting cancer metabolism

Journal of the National Cancer Institute - Monographs

Volumn 2015, Issue 51, 2015, Pages 81-86

  Lord, Simon R ^a   Patel, Neel ^b   Liu, Dan ^b   Fenwick, John ^b   Gleeson, Fergus ^b   Buffa, Francesca ^b   Harris, Adrian L ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BEVACIZUMAB; BIOLOGICAL MARKER; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHODIESTERASE III; PROGESTERONE RECEPTOR; PROTEIN P53; SOMATOMEDIN C; TUMOR NECROSIS FACTOR RECEPTOR 1; ANTIDIABETIC AGENT; TRANSCRIPTOME; TUMOR MARKER;

AMINO ACID SYNTHESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG RESPONSE; DRUG TARGETING; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE SEQUENCE; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIVER CELL CARCINOMA; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETICS; METABOLOME; NEOADJUVANT THERAPY; PROCEDURES;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METABOLOME; METFORMIN; NEOADJUVANT THERAPY; TRANSCRIPTOME;

EID: 84932630141     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgv011     Document Type: Article

References (39)

1. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.
2. Fendt SM, Bell EL, Keibler MA, et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013;73(14):4429-4438.
3. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99(7):989-994.
4. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006;66(12):5977-5980.
5. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3(11):1451-1461.
6. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-1777.
7. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137(2):482-488.
8. Hassan MM, Curley SA, Li D, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116(8):1938-1946.
9. Donadon V, Balbi M, Ghersetti M, et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol. 2009;15(20):2506-2511.
10. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297-3302.
11. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69(19):7507-7511.
12. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-3586.
13. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008;110(2):246-250.
14. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol. 2010;116(1):92-98.
15. Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007;64(10):1290-1302.
16. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223-228.
17. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
18. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010;120(7):2355-2369.
19. A phase III randomized trial of metformin vs placebo in early stage breast cancer. Clinicaltrials.gov Web site. https://clinicaltrials.gov/ct2/show/NCT01101438?term=metformin+breast+cancer&rank=8. Updated April 10, 2015. Accessed April 17, 2015.
20. Mehta S, Hughes NP, Buffa FM, et al. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J Natl Cancer Inst Monogr. 2011;2011(43):71-74.
21. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol. 2012;30(21):2593-2600.
22. Cazzaniga M, Decensi A, Pruneri G. Effect of metformin on apoptosis in a presurgical trial in non-diabetic patients with breast cancer. Cancer Res. 2012;72(24 suppl):116s.
23. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat. 2011;128(3):783-794.
24. Kalinsky K, Crew KD, Refice S. Pre-surgical trial of metformin in overweight and obese, multi-ethnic patients with newly diagnosed breast cancer. Cancer Res. 2012;72(24 suppl):117s.
25. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. 2012;135(3):821-830.
26. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50(1):88-99.
27. Habibollahi P, van den Berg NS, Kuruppu D, Loda M, Mahmood U. Metformin-an adjunct antineoplastic therapy-divergently modulates tumor metabolism and proliferation, interfering with early response prediction by 18F-FDG PET imaging. J Nucl Med. 2013;54(2):252-258.
28. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32(4):623-48; discussion 649.
29. de Geus-Oei LF, Visser EP, Krabbe PF, et al. Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med. 2006;47(6): 945-949.
30. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer. 2010;102(2):428-435.
31. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158-5165.
32. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18) fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20(2):379-387.
33. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.
34. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. 2012;481(7381):385-388.
35. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422-1431.
36. Diraison F, Pachiaudi C, Beylot M. Measuring lipogenesis and cholesterol synthesis in humans with deuterated water: use of simple gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 1997;32(1): 81-86.
37. Diraison F, Moulin P, Beylot M. Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 2003;29(5):478-485.
38. Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN. Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes. 2002;51(9):2684-2690.
39. Pinhel IF, Macneill FA, Hills MJ, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res. 2010;12(5):R76.